217 related articles for article (PubMed ID: 32894760)
1. Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia.
Zhang H; Liu AP; Devidas M; Lee SH; Cao X; Pei D; Borowitz M; Wood B; Gastier-Foster JM; Dai Y; Raetz E; Larsen E; Winick N; Bowman WP; Karol S; Yang W; Martin PL; Carroll WL; Pui CH; Mullighan CG; Evans WE; Cheng C; Hunger SP; Relling MV; Loh ML; Yang JJ
J Natl Cancer Inst; 2021 Apr; 113(4):408-417. PubMed ID: 32894760
[TBL] [Abstract][Full Text] [Related]
2. Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype.
Migliorini G; Fiege B; Hosking FJ; Ma Y; Kumar R; Sherborne AL; da Silva Filho MI; Vijayakrishnan J; Koehler R; Thomsen H; Irving JA; Allan JM; Lightfoot T; Roman E; Kinsey SE; Sheridan E; Thompson P; Hoffmann P; Nöthen MM; Mühleisen TW; Eisele L; Zimmermann M; Bartram CR; Schrappe M; Greaves M; Stanulla M; Hemminki K; Houlston RS
Blood; 2013 Nov; 122(19):3298-307. PubMed ID: 23996088
[TBL] [Abstract][Full Text] [Related]
3. GATA3 germline variant is associated with CRLF2 expression and predicts outcome in pediatric B-cell precursor acute lymphoblastic leukemia.
Madzio J; Pastorczak A; Sedek L; Braun M; Taha J; Wypyszczak K; Trelinska J; Lejman M; Muszynska-Roslan K; Tomasik B; Derwich K; Koltan A; Kazanowska B; Irga-Jaworska N; Badowska W; Matysiak M; Kowalczyk J; Styczynski J; Fendler W; Szczepanski T; Mlynarski W
Genes Chromosomes Cancer; 2019 Sep; 58(9):619-626. PubMed ID: 30859636
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia.
Yang JJ; Cheng C; Devidas M; Cao X; Campana D; Yang W; Fan Y; Neale G; Cox N; Scheet P; Borowitz MJ; Winick NJ; Martin PL; Bowman WP; Camitta B; Reaman GH; Carroll WL; Willman CL; Hunger SP; Evans WE; Pui CH; Loh M; Relling MV
Blood; 2012 Nov; 120(20):4197-204. PubMed ID: 23007406
[TBL] [Abstract][Full Text] [Related]
5. GATA3 rs3824662 gene polymorphism as possible risk factor in a cohort of Egyptian patients with pediatric acute lymphoblastic leukemia and its prognostic impact.
Mosaad YM; Elashery R; Darwish A; Sharaf Eldein OA; Barakat T; Marouf S; Abou El-Khier NT; Youssef LF; Fawzy IM
Leuk Lymphoma; 2017 Mar; 58(3):689-698. PubMed ID: 27684731
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.
Yang JJ; Cheng C; Yang W; Pei D; Cao X; Fan Y; Pounds SB; Neale G; Treviño LR; French D; Campana D; Downing JR; Evans WE; Pui CH; Devidas M; Bowman WP; Camitta BM; Willman CL; Davies SM; Borowitz MJ; Carroll WL; Hunger SP; Relling MV
JAMA; 2009 Jan; 301(4):393-403. PubMed ID: 19176441
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.
Borowitz MJ; Wood BL; Devidas M; Loh ML; Raetz EA; Salzer WL; Nachman JB; Carroll AJ; Heerema NA; Gastier-Foster JM; Willman CL; Dai Y; Winick NJ; Hunger SP; Carroll WL; Larsen E
Blood; 2015 Aug; 126(8):964-71. PubMed ID: 26124497
[TBL] [Abstract][Full Text] [Related]
8. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse.
Perez-Andreu V; Roberts KG; Harvey RC; Yang W; Cheng C; Pei D; Xu H; Gastier-Foster J; E S; Lim JY; Chen IM; Fan Y; Devidas M; Borowitz MJ; Smith C; Neale G; Burchard EG; Torgerson DG; Klussmann FA; Villagran CR; Winick NJ; Camitta BM; Raetz E; Wood B; Yue F; Carroll WL; Larsen E; Bowman WP; Loh ML; Dean M; Bhojwani D; Pui CH; Evans WE; Relling MV; Hunger SP; Willman CL; Mullighan CG; Yang JJ
Nat Genet; 2013 Dec; 45(12):1494-8. PubMed ID: 24141364
[TBL] [Abstract][Full Text] [Related]
9. Association of germline genetic variants in RFC, IL15 and VDR genes with minimal residual disease in pediatric B-cell precursor ALL.
Dawidowska M; Kosmalska M; Sędek Ł; Szczepankiewicz A; Twardoch M; Sonsala A; Szarzyńska-Zawadzka B; Derwich K; Lejman M; Pawelec K; Obitko-Płudowska A; Pawińska-Wąsikowska K; Kwiecińska K; Kołtan A; Dyla A; Grzeszczak W; Kowalczyk JR; Szczepański T; Ziętkiewicz E; Witt M
Sci Rep; 2016 Jul; 6():29427. PubMed ID: 27427275
[TBL] [Abstract][Full Text] [Related]
10. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013.
Olsson L; Ivanov Öfverholm I; Norén-Nyström U; Zachariadis V; Nordlund J; Sjögren H; Golovleva I; Nordgren A; Paulsson K; Heyman M; Barbany G; Johansson B
Br J Haematol; 2015 Sep; 170(6):847-58. PubMed ID: 26018335
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
12. Novel susceptibility variants at the
Qian M; Xu H; Perez-Andreu V; Roberts KG; Zhang H; Yang W; Zhang S; Zhao X; Smith C; Devidas M; Gastier-Foster JM; Raetz E; Larsen E; Burchard EG; Winick N; Bowman WP; Martin PL; Borowitz M; Wood B; Antillon-Klussmann F; Pui CH; Mullighan CG; Evans WE; Hunger SP; Relling MV; Loh ML; Yang JJ
Blood; 2019 Feb; 133(7):724-729. PubMed ID: 30510082
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Davies SM; Borowitz MJ; Rosner GL; Ritz K; Devidas M; Winick N; Martin PL; Bowman P; Elliott J; Willman C; Das S; Cook EH; Relling MV
Blood; 2008 Mar; 111(6):2984-90. PubMed ID: 18182569
[TBL] [Abstract][Full Text] [Related]
14. A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.
Perez-Andreu V; Roberts KG; Xu H; Smith C; Zhang H; Yang W; Harvey RC; Payne-Turner D; Devidas M; Cheng IM; Carroll WL; Heerema NA; Carroll AJ; Raetz EA; Gastier-Foster JM; Marcucci G; Bloomfield CD; Mrózek K; Kohlschmidt J; Stock W; Kornblau SM; Konopleva M; Paietta E; Rowe JM; Luger SM; Tallman MS; Dean M; Burchard EG; Torgerson DG; Yue F; Wang Y; Pui CH; Jeha S; Relling MV; Evans WE; Gerhard DS; Loh ML; Willman CL; Hunger SP; Mullighan CG; Yang JJ
Blood; 2015 Jan; 125(4):680-6. PubMed ID: 25468567
[TBL] [Abstract][Full Text] [Related]
15. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
[TBL] [Abstract][Full Text] [Related]
16.
Al-Zayan NR; Ashour MJ; Abuwarda HN; Sharif FA
Pediatr Hematol Oncol; 2024; 41(2):103-113. PubMed ID: 37578068
[TBL] [Abstract][Full Text] [Related]
17. Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute Lymphoblastic Leukemia in Children.
Qian M; Zhao X; Devidas M; Yang W; Gocho Y; Smith C; Gastier-Foster JM; Li Y; Xu H; Zhang S; Jeha S; Zhai X; Sanda T; Winter SS; Dunsmore KP; Raetz EA; Carroll WL; Winick NJ; Rabin KR; Zweidler-Mckay PA; Wood B; Pui CH; Evans WE; Hunger SP; Mullighan CG; Relling MV; Loh ML; Yang JJ
J Natl Cancer Inst; 2019 Dec; 111(12):1350-1357. PubMed ID: 30938820
[TBL] [Abstract][Full Text] [Related]
18. Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.
Schumich A; Maurer-Granofszky M; Attarbaschi A; Pötschger U; Buldini B; Gaipa G; Karawajew L; Printz D; Ratei R; Conter V; Schrappe M; Mann G; Basso G; Dworzak MN;
Pediatr Blood Cancer; 2019 May; 66(5):e27590. PubMed ID: 30561169
[TBL] [Abstract][Full Text] [Related]
19. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic significance and risk factors of minimal residual disease ≥1% on 19th day of induction chemotherapy in children with acute lymphoblastic leukemia].
Yu J; Yi T; Lin G; Wen J; Chen L; Chen J; Wu X
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Feb; 40(2):255-261. PubMed ID: 32376526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
